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Abstract 
Purpose 
Preimplantation genetic diagnosis (PGD) is a reproductive option for BRCA1/2 mutation 
carriers wishing to avoid transmission of the predisposition for hereditary breast and ovarian 
cancer (HBOC) to their offspring. Embryos obtained by in vitro fertilisation (IVF/ICSI) are 
tested for the presence of the mutation, only BRCA-negative embryos are transferred into the 
uterus. The suitability and outcome of PGD for HBOC is evaluated.  
Methods 
Observational cohort study on PGD treatments for HBOC carried out in two of Western-
Europe’s largest PGD centres from 2006 until 2012. Male carriers, asymptomatic female 
carriers, and breast cancer survivors were eligible. If available, PGD on embryos 
cryopreserved before chemotherapy was possible. Generic PGD-PCR tests were developed 
based on haplotyping, if necessary combined with mutation detection. 
Results 
70 couples underwent PGD for BRCA1/2. 42/71 carriers (59.2%) were female, six (14.3%) of 
whom have had breast cancer prior to PGD. In total, 145 PGD cycles were performed. 720 
embryos were tested, identifying 294 (40.8%) as BRCA-negative. Of fresh IVF/PGD cycles, 
23.9% resulted in a clinical pregnancy. Three cycles involved PGD on embryos cryopreserved 
before chemotherapy; two of these women delivered a healthy child. Overall, 38 children 
were liveborn. Two BRCA1 carriers were diagnosed with breast cancer shortly after PGD 
treatment, despite negative screening prior to PGD. 
Conclusions 
PGD for HBOC proved to be suitable, yielding good pregnancy rates for asymptomatic 
carriers as well as breast cancer survivors. Because of two cases of breast cancer shortly after 
treatment, maternal safety of IVF(/PGD) in female carriers needs further evaluation. 
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PGD, preimplantation genetic diagnosis 
HBOC, hereditary breast and ovarian cancer 
IVF, in vitro fertilisation 
ICSI, intracytoplasmic sperm injection 
BMI, body mass index 
MRI, magnetic resonance imaging 
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FET, frozen/thawed embryo transfer cycle 
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Purpose 
Hereditary breast and ovarian cancer (HBOC) is an autosomal dominant cancer predisposition 
syndrome caused by mutations in tumor suppressor genes Breast Cancer 1 (BRCA1, 17q21.31, 
MIM 113705) or Breast Cancer 2 (BRCA2, 13q13.1, MIM 600185). Female carriers have 
strongly increased risks for both breast and ovarian cancer, estimated at 57% and 49% for 
breast cancer and 40% and 18% for ovarian cancer for BRCA1 and BRCA2 respectively, at the 
age of 70 [1]. In comparison, women in the United Kingdom in general have a 12.5% lifetime 
risk for invasive breast cancer and 1.9% for invasive ovarian cancer [2,3]. The prevalence of 
germline BRCA1/2 mutations is estimated at 0.1-1.0% in the general population, making 
HBOC one of the more prevalent autosomal dominant genetic disorders [4,5].  
Carriers of a BRCA1/2 mutation have a 50% risk of passing this predisposition to their 
offspring. There are several reproductive options to circumvent this, but only two lead to a 
child genetically related to both partners: prenatal diagnosis and preimplantation genetic 
diagnosis (PGD). Prenatal diagnosis on the one hand, involves genetic testing of a fetus for 
the presence of a familial BRCA1/2 mutation during pregnancy, followed by pregnancy 
termination in case of an unfavourable result. Although applied on a small scale, reports 
regarding clinical experience with prenatal diagnosis for HBOC are not available in the 
literature to date. Preimplantation genetic diagnosis (PGD) on the other hand, involves in vitro 
fertilisation (IVF) with intracytoplasmic sperm injection (ICSI), followed by genetic testing of 
the embryos for the presence of a familial BRCA1/2 mutation before intrauterine transfer. 
PGD has been successfully applied since 1990 for an expanding list of monogenic disorders 
and chromosomal abnormalities [6]. In 2003, the Ethics Taskforce of the European Society of 
Human Reproduction and Embryology stated that it is acceptable to perform PGD for late 
onset and multifactorial diseases, including HBOC [7]. In 2005, a survey among BRCA1/2 
carriers was carried out to investigate the public attitude towards PGD for HBOC, an 
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important step in the legalization of PGD for hereditary cancer syndromes in the United 
Kingdom [8,9]. This study and other opinion surveys have shown that most BRCA carriers 
consider PGD for HBOC as an acceptable reproductive option, although only a minority of 
them would consider using PGD personally [9,10]. However, appliance of both prenatal 
diagnosis as well as PGD for HBOC remains controversial, considering the reduced 
penetrance of the condition, its late onset, and availability of prophylactic and therapeutic 
options [11].
 
Previous research has shown that safety of ovarian stimulation for IVF is an 
important consideration for female BRCA carriers when deciding on PGD [12]. This topic has 
not extensively been studied in female BRCA1/2 carriers to date, although one case-control 
study did not find a significant adverse effect on the incidence of breast cancer [13]. Up to 
now, some case-reports and small case-series have been reported on the clinical experience 
with PGD for HBOC, with Jasper and colleagues as the first to report a pregnancy in 2008 
[14-18].  
In 2006 PGD for HBOC was started at the Universitair Ziekenhuis Brussel, Belgium 
(hereafter named centre A) and in 2008 at Maastricht University Medical Centre +, the 
Netherlands (hereafter centre B), two large centres for PGD in Western Europe [19].
 
In this 
study we aim to determine suitability of this treatment, for both asymptomatic male and 
female BRCA1/2 carriers as well as BRCA-positive female breast cancer survivors, in terms of 
genetic results, pregnancy rates, and successful deliveries. Additionally, we report on cancer 
outcome of female mutation carriers.  
 
Methods 
Patients 
Observational cohort study on PGD cycles performed for BRCA1/2 mutations from the onset 
in 2006 until 1-1-2012. Couples of whom at least one partner was known to have a BRCA1/2 
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mutation were referred for PGD counseling to our centres. We provided them with verbal and 
written information regarding the PGD procedure (including IVF and ICSI, embryo biopsy, 
single cell analysis, chance of pregnancy, and risk of misdiagnosis). We considered female 
age > 40 years and female body mass index (BMI) > 30 kg/m² as relative contra-indications 
for PGD, whereas female age ≥ 43 years and female BMI ≥ 35 kg/m² were absolute contra-
indications.  
 
Gynaecological screening procedures 
We performed gynaecological and andrological examination, including sperm analysis, 
female hormonal assessment, and virology tests of both partners, to ensure suitability of the 
couple for IVF/ICSI treatment. In cases where embryos were harvested by IVF/ICSI prior to 
chemotherapy, appliance of PGD on these cryopreserved embryos was possible.  
 
Oncological screening procedures 
We screened female carriers without a prophylactic mastectomy in the past for the presence of 
occult breast cancer before admission to the PGD program. In addition to annual screening 
procedures, at least a magnetic resonance imaging (MRI) of the breasts was performed prior 
to the start of PGD [20,21].
 
BRCA-positive women with a history of breast cancer were 
eligible for PGD if they had been free of malignant disease for at least two years after their 
oncologic treatment. Depending on age and familial phenotype, we screened female carriers 
for the presence of occult ovarian carcinoma prior to admission to the PGD program by 
gynaecological and ultrasound examination and CA-125 determination in blood. 
 
PGD procedures 
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Prior to the introduction of the PGD program, we obtained medical ethical approval of the 
institutional review boards at both centres. All couples gave their informed consent before 
PGD was started. We performed IVF and PGD according to international guidelines [22,23] 
and used ICSI for fertilisation to avoid contamination of the zona pellucida with spermatozoa, 
which may disturb the PGD analysis. We biopsied obtained embryos three days after 
fertilisation. Single cell analysis of the blastomeres was performed using polymerase chain 
reaction (PCR), based on haplotyping of at least two informative flanking microsatellite 
markers on each side of the BRCA1/2 loci. In a minority of cases this generic test was not 
informative. In these cases we set up a mutation specific protocol, based on identifying the 
private mutation in combination with at least one informative marker (table 1) [15,24].
 
After 
single cell analysis we classified the embryos as affected (BRCA1/2 mutation present), 
unaffected (BRCA1/2 mutation absent), abnormal (abnormal genotype, e.g. haploidy or 
triploidy) or no diagnosis (no test result or inconclusive BRCA1/2 status). Subsequently, one 
or two unaffected embryos were transferred into the uterus at day four or five postfertilisation. 
The number of transferred embryos depended on embryo quality, female age, number of 
previous unsuccessful attempts, and the couples’ preference for transferring only one embryo. 
Supernumerary unaffected embryos of sufficient quality were cryopreserved and transferred 
in a subsequent cycle after thawing (defined as ‘frozen/thawed embryo transfer cycle, FET’) 
[25]. FETs were included in the survey if they followed a fresh IVF/PGD cycle during the 
study period and in case the embryo transfer was performed before 1-10-2012. 
Pregnancy rates are reported as positive hCG tests as well as clinical pregnancy rates. The 
clinical pregnancy rate was diagnosed according to the standard definition, i.e. a pregnancy 
diagnosed by transvaginal ultrasonographic visualization of one or more gestational sacs or 
definite clinical signs of pregnancy, including ectopic pregnancy. A delivery was defined as 
the birth of one or more fetuses after at least 20 completed weeks of gestational age [25]. 
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Couples were given the option of prenatal diagnosis to confirm PGD outcome. Follow-up of 
pregnancies and children was carried out at centre A as described earlier [26]
 
and at centre B 
using a questionnaire. At the end of the study time (i.e. 1-10-2012) all female BRCA1/2 
carriers were contacted by telephone and asked for their health status, including diagnosis of 
breast cancer since the last PGD treatment and prophylactic surgeries performed in the 
meantime.   
 
Statistical analysis 
Statistical analyses were performed using SPSS 18.0.0. Data are presented as mean and 
standard deviation (for continuous variables) or number of cases and percentages (for 
categorical variables).  
 
Results 
Patients  
70 couples underwent PGD for HBOC. In one couple the male and female partner were both a 
BRCA1 carrier. Of 71 carriers, 42 were female (59.2%). Of the female carriers, 28 (66.7%) 
had a BRCA1 mutation and fourteen (33.3%) a BRCA2 mutation. Of 29 male carriers, 21 
(72.4%) had a BRCA1 mutation and eight (27.6%) a BRCA2 mutation. Over a quarter of 
female carriers (11/42, 26.2%) had undergone prophylactic breast surgery before PGD. Six 
out of 42 female carriers (14.3%) had a history of breast cancer (table 2).  
 
Outcome  
In total, 145 PGD cycles were carried out (table 3). Three of these cycles involved PGD on 
embryos cryopreserved before chemotherapy because of breast cancer. Overall, 720 embryos 
were tested for BRCA1/2, identifying 294 (40.8%) as unaffected, 311 (43.2%) as affected, 70 
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(9.7%) as abnormal, and 45 (6.3%) as having no diagnosis. In 87 out of 142 fresh IVF/PGD 
cycles (61.3%) one or two embryos were transferred, resulting in 37 positive hCG tests and 34 
clinical pregnancies. Clinical pregnancy rates were 23.9% per cycle started and 39.1% per 
embryo transfer. Subsequently to these fresh IVF/PGD cycles, 34 frozen/thawed embryo 
transfer cycles (FETs) were performed, resulting in 10 positive hCG tests and 9 clinical 
pregnancies (clinical pregnancy rate 26.5% per embryo transfer, table 3).  
Three out of six women with a history of breast cancer had harvested embryos prior to 
chemotherapy and underwent PGD on these embryos. Two of them delivered a healthy child 
after PGD. Subsequently, two of these three women were denied a fresh ovarian stimulation 
for PGD because of a diminished ovarian reserve after chemotherapy. The third woman, and 
the three women who did not cryopreserve embryos, were treated in one or more fresh 
IVF/PGD cycles. One of them delivered a healthy child (table 4).  
In centre A, four couples pregnant after PGD for BRCA1 requested prenatal diagnosis to 
confirm PGD diagnosis. In two cases a chorionic villus biopsy was performed (one in a twin 
pregnancy), amniocentesis in the other two. All results were BRCA-negative, confirming PGD 
outcome. None of the pregnant couples treated in centre B opted for prenatal diagnosis to 
confirm PGD diagnosis. 
Out of a total of 45 clinical pregnancies, 36 (80.0%) proceeded to birth. The other 9 resulted 
in a miscarriage or concerned ectopic pregnancies. Of 41 children (31 singletons and five 
twins), 38 (92.7%) were born alive. One singleton pregnancy was terminated at 23 weeks of 
gestation because of multiple congenital malformations based on a de novo chromosomal 
abnormality (deletion 3q26.2 and duplication 15q11.2). Two other children were stillborn: 
one member of twins died in utero at 24 weeks of gestation for unknown reasons; the other 
sibling was born alive at 33 weeks. One member of another twin died in utero due to 
abruption of the placenta at 35 weeks of gestation. The other sibling was born alive. One 
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singleton pregnancy was complicated by premature labour at 26 weeks of gestation. At the 
end of study time, at age 2.5 years, the girl born was doing well.  
 
Follow-up of female BRCA1/2 carriers 
Two BRCA1 carriers (one in each PGD centre) were diagnosed with early stage triple 
negative breast cancer within two, respectively three months after their first ovarian 
stimulation for IVF/PGD, despite having a negative breast screening shortly before (table 5). 
One of them had a history of contralateral breast cancer. Both women did not become 
pregnant after PGD. 
One female carrier did not want to be contacted to check on her medical condition after PGD 
for personal reasons; all other female carriers were contacted. None of them have been 
diagnosed with breast cancer after PGD. Mean exposed follow-up time (from ovarian 
stimulation until end of follow-up or until prophylactic breast surgery) was 27.5 months 
(range 2 to 68 months).  
 
Conclusions 
This study establishes the clinical suitability of PGD for BRCA1/2 mutations in both 
asymptomatic carriers and BRCA-positive female breast cancer survivors, either in a fresh 
IVF/PGD cycle as well as on embryos harvested before chemotherapy. A series of 145 
consecutive PGD cycles is presented, the first large series of PGD for HBOC. When 
compared to the outcome of PGD for autosomal dominant disorders as reported by the 
European Society of Human Reproduction and Embryology PGD consortium, our clinical 
pregnancy rates are in line with these data (39.1% vs. 26.7% per embryo transfer respectively) 
[6].
 
Two factors known to influence reproductive outcome in BRCA1/2 carriers were present 
in our series: on the one hand, the women included in our survey were younger than those 
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reported by the PGD consortium (29.6 versus 34 years), which is a favourable factor for 
reproductive outcome. On the other hand, it was hypothesized that BRCA1/2 mutations may 
unfavourably reduce ovarian reserve due to accumulated DNA damage secondary to 
inadequate DNA repair [27]. In total, 49 pregnancies were established, resulting in the birth of 
31 singletons and five twins. The observation of two perinatal deaths and one pregnancy 
termination because of major malformations in our cohort of 41 children is presumed to be an 
coincidence; PGD is not associated with an increased risk for perinatal deaths or major 
congenital malformations [26].
 
However, the health of children born after PGD (for HBOC) 
needs to be subject to further research and longer follow-up.  
Analysis of the blastomeres for the presence of BRCA1/2 reflected the suspected 50/50 
distribution of unaffected (41%) versus affected (43%) embryos. Almost 10% of the embryos 
showed fertilisation abnormalities (e.g. haploidy or triploidy), which is not an uncommon 
finding in preimplantation embryos. We presume that the diagnostic accuracy of PGD 
analyses based on PCR is high; an earlier study in one of our centres reported a false-negative 
rate of 0.5% in surplus embryos [28]. This is in accordance to the reported misdiagnosis rate 
of 0.4% in pregnancies established after PGD for monogenic disorders detected by PCR 
analysis [29]. However, since only few of the pregnant couples opted for prenatal diagnosis, 
definitive confirmation of PGD diagnosis was not possible in the majority of cases. Because 
genetic testing for adult-onset disorders in childhood is ethically controversial and therefore 
discouraged [30], postnatal testing after PGD for HBOC was not performed.  
In addition to the suitability of PGD for HBOC following a fresh IVF/PGD cycle, we also 
demonstrated that PGD on embryos harvested prior to chemotherapy is an applicable option: 
two out of three women treated, delivered a healthy child. These results stress the importance 
of timely counseling regarding fertility preserving options available for young women with 
breast cancer [31,32].
 
This is important not only to retain an option to reproduce in case 
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oncological treatment would cause infertility, but also because PGD can be applied on 
harvested embryos in case of BRCA carriership. Known BRCA status at the moment of 
fertility preservation is not a prerequisite, provided that ICSI is used for fertilisation to keep 
the possibility of PCR analysis. When cryopreserved embryos of sufficient quality are 
available, it is preferable to use these first for PGD. This can save the patient a new ovarian 
stimulation, which may be less successful in case of a diminished ovarian reserve after 
oncological treatment.  
Two women in our cohort were diagnosed with breast cancer after their first IVF/PGD cycle. 
One of these women had a history of contralateral breast cancer. Both women were carrier of 
a BRCA1 mutation. BRCA1-associated tumors are characterized by a higher proportion of 
interval tumors and a younger age and more often an unfavourable size at diagnosis, when 
compared with BRCA2-associated tumors. Besides, invasive BRCA1 breast tumors are often 
high grade and rapidly growing [33,34]. While a possible linkage between IVF treatment and 
breast cancer risk has extensively been studied in the general population [35], safety of IVF 
with regards to the risk for breast cancer has not been systematically studied in female 
BRCA1/2 carriers. Gonadotropin use for IVF results in a rise in estrogens. Several 
observations suggest an influence of (prolonged) exposure to estrogens on incidence of 
BRCA-related breast cancers, although approximately 80% of BRCA1-tumors are estrogen and 
progesterone receptor negative [36]. Kotsopoulos and colleagues conducted a matched case-
control study to examine the influence of fertility medications for IVF treatment on breast 
cancer risk in BRCA1/2 carriers. They were able to include 26 carriers with a history of 
gonadotropin use, sixteen of whom were diagnosed with breast cancer (multivariate OR 2.32, 
95% CI 0.91-5.95, p = 0.08). The sample size of the study may have been too limited however 
to detect a significant adverse effect of gonadotropin use on breast cancer risk in BRCA1/2 
carriers [13]. One study reported an association between fertility treatment and an increased 
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risk for breast cancer in women with a positive family history for breast cancer (RR 1.4; 95% 
CI 1.0-1.9) [37], while others did not find fertility (treatment) and breast cancer to be 
associated in these women [38,39]. It is possible, yet unproven that administering 
gonadotropins may have led to an acceleration in growth of pre-existing, but not yet 
detectable, tumors in the two affected BRCA1 carriers in our cohort. Therefore we stress the 
importance of screening of the breasts before admission to IVF(/PGD) treatment, as well as 
after treatments. Larger studies are needed to elucidate whether our observation is just a 
coincidental finding in a population with a high a priori risk for breast cancer, or whether a 
causal relationship exists. 
This study has some limitations. Firstly, the sample size is relatively small. Secondly, 
reliability of PGD diagnosis could not be confirmed; it was ethically impossible to test BRCA-
status of the children born after PGD, due to the late onset character of the predisposition and 
the children’s autonomy. Finally, our study was not primarily designed to assess maternal 
safety of IVF in female carriers. 
 
Recommendations 
This survey shows that PGD for HBOC is an established and suitable technique with good 
reproductive outcome, which should be offered as part of a comprehensive approach to the 
counseling and treatment of all BRCA1/2 patients. It is important that medical professionals 
involved in the care for BRCA carriers are aware of this reproductive option, in order to 
inform patients timely and to refer them, at request, to a specialized PGD centre. In case of a 
newly diagnosed breast cancer in a woman of reproductive age, it is essential to be aware of 
the possibility of PGD if and when BRCA carriership would turn out. Given the complex 
medical history of female carriers and our observation of two breast cancer cases after PGD 
treatment, a multidisciplinary approach is a prerequisite in PGD practice. In addition, 
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oncological screening of female carriers before admission to the treatment, as well as careful 
follow-up, is required.   
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Table 1: PGD strategies for BRCA1/2 mutations 
 Centre Aa Centre Bb 
Indirect testing BRCA1 mutationsc BRCA1STR24CA, BRCA1STR20TG, 
BRCA1STR16GA, BRCA1STR4, 
BRCA1STR21CA, D17S2249, D17S1323, 
D17S855 
D17S932, BRCA1_dis24AC, D17S950, 
D17S1814, D17S800, D17S1787 
Indirect testing BRCA2 mutationsc BRCA2STR19TG, BRCA2STR20GT, 
BRCA2STR18AC, D13S260, D13S171 
D13S171, D13S1695, BRCA2_dist18AC, 
D13S267, D13S289, D13S260, D13S1698, 
BRCA2STR19 
Alkaline lysis buffer 50 mM DTT, 200 mM NaOH 50 mM DTT, 200 mM NaOH 
Freezing post tubing 30’ -20° 30’ -20°C 
Decontamination UV-C UV-C 
Polymerase Qiagen Multiplex PCR KIT Qiagen Multiplex PCR KIT 
Split for multiplex PCR No No 
Genetic analyser ABI3730xl ABI3730xl 
 
Abbreviations: PGD, preimplantation genetic diagnosis, BRCA1, breast cancer gene 1, BRCA2, breast cancer 
gene 2, PCR, polymerase chain reaction 
 
a  Universitair Ziekenhuis Brussel, Belgium 
b  Maastricht University Medical Centre +, the Netherlands 
c Many of the markers have not been published; the primer sequences were designed in-house and are available 
upon request. In case indirect testing was not possible due to either non-informativity of markers or availability 
of family members, mutation-specific tests were developed including the typical familial mutation combined 
with at least 2 markers 
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Table 2: Couples’ characteristics 
 
 n = 70 
Nulliparity prior to PGD 60 (85.7%) 
At-risk person 
       Male  
       Female 
       Both partners 
 
28 (40.0%)  
41 (58.6%) 
1a   (1.4%) 
Mutation 
       BRCA1  
       BRCA2 
 
48 (68.6%) 
22 (31.4%) 
Mean female age in years (SD) 
       Female carriers 
29.5 (3.6) 
29.6 (3.7) 
Mean female BMI (SD) 23.1 (3.4) 
Female carriers with prophylactic mastectomy  11 (26.2%) 
Female carriers with history of breast cancer  6 (14.3%) 
 
Abbreviations: PGD, preimplantation genetic diagnosis, BRCA1, breast cancer gene 1, BRCA2, breast cancer 
gene 2, SD, standard deviation, BMI, Body Mass Index (kg/m
2
) 
 
a  Both partners were BRCA1 carrier, only unaffected embryos were eligible for embryo transfer 
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Table 3: Reproductive outcome of PGD for HBOC (n=70 couples)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PGD, preimplantation genetic diagnosis, HBOC, hereditary breast and ovarian cancer, IVF, in vitro fertilisation, 
SD, standard deviation, hCG, human chorionic gonadotropin, FET, frozen/thawed embryo transfer cycle, N/A, 
not applicable 
  
a  One couple, who underwent two IVF/PGD cycles, requested cryopreservation of unaffected embryos because 
of prophylactic salpingo-oophorectomy. In five other IVF/PGD cycles unaffected embryos were cryopreserved 
to postpone embryo transfer for different reasons (ovarian hyperstimulation syndrome (n=2), insufficient 
endometrial buildup (n=2), and delay of PGD results (n=1) 
 
 
 IVF/PGD cycles PGD on embryos 
cryopreserved before 
chemotherapy 
PGD treatments started 142 3 
      Mean treatments started 
      per couple (SD) 
2.1 (1.3) 1 
Biopsied embryos 720 
       Unaffected  294 (40.8%) 
       Affected  311 (43.2%) 
       Abnormal 70 (9.7%) 
       No diagnosis 45 (6.3%) 
Ovarian stimulations to embryo 
transfera 
87 (61.3%) N/A 
Positive hCG tests 
       % per oocyte retrieval 
       % per embryo transfer  
Clinical pregnancies 
       % per oocyte retrieval 
       % per embryo transfer 
 
37 
30.3% 
42.5% 
34 
27.9% 
39.1% 
N/A 
FET 34 3 
Positive hCG tests 
after FET 
       % per FET after IVF/PGD 
       % per FET of embryo(s) 
       cryopreserved before 
       chemotherapy 
Clinical pregnancies after FET 
       % per FET after IVF/PGD 
       % per FET of embryo(s)    
      cryopreserved before    
      chemotherapy 
10 
 
29.4% 
 
 
 
9 
26.5% 
2  
 
 
66.7% 
 
 
2 
 
66.7% 
Pregnancies (total) 49 
Pregnancies ongoing ≥ 12 weeks 
       Lost to follow-up < 12 weeks 
36 
1 
Deliveries (≥ 20 weeks) 
       Singletons 
       Twins 
       Lost to follow-up ≥ 20 weeks  
36 
31 
5 (10 children) 
0 
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Table 4: Characteristics of women with a history of breast cancer before PGD treatment  
 
 Centre Aa Centre Bb 
 Patient Ac  Patient B  Patient C  Patient D  Patient E  Patient F 
Reproductive history None None None None 2005 healthy daughter, 
2007 miscarriage, 2007 
molar pregnancy  
None 
Gynaecologic history None None None 2007 unilateral salpingo-
oophorectomy 
(inflammation) 
2007 dilatation and 
curettage  
None 
Gene mutation BRCA1 BRCA1 BRCA1 BRCA2 BRCA1 BRCA2 
Age at breast cancer diagnosis 31 29 26 33 33 32 
Oncologic treatment 
        Surgery 
         
        Chemotherapy 
        Irradiation 
 
Mastectomy 
 
Yes 
No 
 
Mastectomy 
 
Yes 
Yes 
 
Skin sparing mastectomy 
 
Yes 
Yes 
 
Mastectomy 
 
Yes 
No 
 
Modified radical 
mastectomy 
Yes 
Yes 
 
Lumpectomy 
 
No 
Yes 
Contralateral prophylactic mastectomy No Yes Yes Yes  Yes No 
       
Embryos cryopreserved before 
chemotherapy 
Yes No Yes Yes Yes N/A 
Disease free interval before first PGD 
cycle (yrs) 
2.5 4.0 2.0  3.8 2.8  4.5  
PGD on embryos cryopreserved before 
chemotherapy  
No N/A Yes Yes Yes N/A 
 Outcome  N/A N/A Healthy son born Not pregnant Healthy daughter born N/A 
IVF/PGD after recovery from cancer  Yes Yes Yes No (denied because of 
chemotherapy induced 
infertility) 
No (denied because of 
chemotherapy induced 
infertility) 
Yes 
 Outcome No embryo transfer Not pregnant Ectopic pregnancy  N/A N/A Healthy son born 
 
PGD, preimplantation genetic diagnosis, BRCA1, breast cancer gene 1, BRCA2, breast cancer gene 2, IVF, in vitro fertilisation, N/A, not applicable 
 
a  Universitair Ziekenhuis Brussel, Belgium 
b  Maastricht University Medical Centre +, the Netherlands 
c Same patient as patient G in table 5. This patient was diagnosed with breast cancer and underwent one IVF cycle prior to chemotherapy to cryopreserve embryos (n=6). After 
recovery, she chose for a new ovarian stimulation for IVF/PGD instead of using her cryopreserved embryos first. After IVF/PGD, she was diagnosed with contralateral breast 
cancer and needed chemotherapy again (see table 5). She underwent two IVF cycles to cryopreserve embryos (n=1). Besides, a laparoscopic unilateral oophorectomy took 
place to cryopreserve the ovary. After recovery of the second breast cancer, she conceived spontaneously and gave birth to a twin 
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Table 5: Overview of women who were diagnosed with breast cancer after PGD treatment 
 
 Patient Ga Patient H 
PGD Centre Centre Ab Centre Bc 
Gene mutation BRCA 1  BRCA 1 
   
Oncologic history prior to PGD Diagnosed with breast cancer in 2006: invasive ductal carcinoma, 
T2mN0M0, triple negative. Treatment consisted of mastectomy and 
chemotherapy 
None 
Reproductive history prior to PGD cycle after which 
breast cancer was diagnosed 
One IVF cycle for fertility preservation prior to chemotherapy in 
2006 (6 embryos). It was the patient’s choice to undergo a new 
ovarian stimulation for PGD instead of using the cryopreserved 
embryos first 
None 
   
Age at breast cancer diagnosis after PGD 34 28 
Last breast screening before PGD One month before PGD, MRI: no abnormalities Two months before PGD, MRI: no abnormalities 
Number of IVF/PGD cycles 1  1  
Outcome IVF/PGD cycle No embryo transfer Not pregnant 
   
Breast cancer diagnosis Two months after PGD, MRI Three months after PGD, MRI 
Pathology Invasive ductal carcinoma, T1cN0M0, triple negative Invasive ductal carcinoma, T1bN1aM0, triple negative 
Treatment   
 Oncologic surgery Mastectomy, SNP  Lumpectomy, axillary lymph node dissection  
 Systemic therapy Yes Yes 
 Irradiation No Yes 
 Prophylactic mastectomy N/A Planned  
Current status No evidence of disease, delivered twin after spontaneous conception 
(see legend table 4) 
No evidence of disease, wishes to continue PGD after recovery of 
prophylactic surgery 
 
PGD, preimplantation genetic diagnosis, BRCA1, breast cancer gene 1, IVF, in vitro fertilisation, MRI, magnetic resonance imaging, SNP, sentinel node procedure, 
N/A, not applicable 
 
a Same patient as patient A in table 4 
b Universitair Ziekenhuis Brussel, Belgium 
c Maastricht University Medical Centre +, the Netherlands 
 
 
